CRISPR Therapeutics reported strong Q3 2026 financial results, with CASGEVY revenue reaching $99 million, up 30% from the previous quarter and nearly six times Q3 2025. The gene-editing therapy CASGEVY gained new approvals for younger children in the UK, UAE, Bahrain, and the US, broadening patient access. The FDA granted advanced therapy designations to CTX310, highlighting its potential in cardiovascular disease. The company also completed enrollment in a Phase 2 trial for CTX611 and announced new leadership appointments, signaling a pivotal phase for its diverse pipeline of gene-editing therapies.
Following CRISPR Therapeutics' announcement of expanded approvals and strong Q3 revenue growth, the stock is currently priced at USD 48.80 on Pluang as of Nov 03, 2026 04:11 WIB. Despite the positive business update, the share price has dipped 5.06% in one day. The company holds a market cap of $4.97 billion and investors on Pluang show full buying interest with 100% buy orders and no sells.
